Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

计划入组 226 人 · 首次发布于 2026 年 3 月 3 日

A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

计划入组 265 人 · 首次发布于 2026 年 3 月 13 日

PsA-TT-007

计划入组 1,500 人

JWK-007

INGN-007

University of Texas Health Science Center at Houston

United States

APR Applied Pharma Research SA

Switzerland

Yuxi Walvax Biotechnology Co., Ltd.

China

Whitehawk Data at WCLC 2026 Position PTK7 as Durable, Treatment-Agnostic ADC Target in EGFR Wild-Type NSCLC

Whitehawk Therapeutics Validates PTK7 as Third Most Abundant ADC Target Across 157,000 Tumor Samples

Whitehawk Therapeutics Advances Two Next-Generation ADCs into Clinical Trials with FDA IND Clearances